

Customer No. 22,869
Appl. No. 10/674,836
January 31, 2007

Atty. Docket No. 082/103
Supplemental Information Disclosure Statement



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of: Gregg B. Morin et al.

Serial No.: 10/674,836

Filing Date: September 29, 2003

Attorney Docket: 082/103C

For: TELOMERASE REVERSE
TRANSCRIPTASE TRANSCRIPTIONAL
REGULATORY SEQUENCES AND
METHODS OF USING

Art Unit: 1635

Examiner: Jon E. Angell

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MAIL STOP AMENDMENT
Commissioner for Patents
P. O. Box 1450
Arlington, VA 22313-1450

Dear Sir:

The information listed in the accompanying form PTO/SB/08 and provided herewith may be material to examination of this application and is submitted in compliance with the duty of disclosure under 37 C.F.R. § 1.56. The Examiner is requested to make this information of record in the application.

A copy of all documents is submitted, except for WO 00/46355, which was previously submitted with the Information Disclosure Statement filed on September 21, 2006. This document was not initialed by the Examiner in the PTO-1449 papers

attached to the Office Action, and is therefore listed again on the Form PTO/SB/08 for the Examiner's convenience.

This Information Disclosure Statement is not to be construed as a representation that a full search for relevant information has been made, that all relevant information has been found, or that the information provided with this Statement is considered to be material to patentability of the claimed invention as defined under 37 CFR § 1.56(b).

This Information Disclosure Statement is being filed after the first Office Action on the merits, but before issuance of a final Office Action or Notice of Allowance, pursuant to 37 C.F.R. § 1.197(c)(2). Authorization to charge Deposit Account 07-1139 (Ref.: 082/103) with the fee of \$180 is provided in the accompanying fee calculation sheet.

Should any other fees be required for further consideration of the application and the enclosed information, the Commissioner is hereby authorized to charge such fees (or credit any overpayment) to the Deposit Account.


Respectfully submitted,



Bart W. Wise
Registration No. 49,029

GERON CORPORATION
230 Constitution Drive
Menlo Park, CA 94025
Telephone: (650) 473-7753
Fax: (650) 473-8654

January 31, 2007



Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/674,836
Filing Date	September 29, 2003
First Named Inventor	Gregg B. MORIN
Art Unit	1635
Examiner Name	Jon E. ANGELL
Attorney Docket Number	082/103

Sheet 1 of 2

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number-Kind-Code	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, where relevant passages or relevant figures appear

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind-Code	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, where relevant passages or relevant figures appear	T
		WO 00/46355 A2	08-10-2000	Geron Corporation		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Trans
		AGHI, M. & MARTUZA, R., "Oncolytic viral therapies – the clinical experience," <i>Oncogene</i> 24:7802-16 (2005).	
		EBERT, O. et al., "Systemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice," <i>Cancer Gene Therapy</i> 12:350-58 (2005).	
		GU, J. & FANG, B., "Telomerase Promoter-Driven Cancer Gene Therapy," <i>Cancer Biol. Ther.</i> 2:4(Suppl. 1):S64-S70 (2003).	
		GU, J. et al., "Tumor-specific Transgene Expression from the Human Telomerase Reverse Transcriptase Promoter Enables Targeting of the Therapeutic Effects of the Bax Gene to Cancers," <i>Cancer Res.</i> 60:5359-64 (2000).	
		IRVING, J. et al., "Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity," <i>Cancer Gene Therapy</i> 11:174-85 (2004).	
		JACOB, D. et al., "Suppression of pancreatic tumor growth in the liver by systemic administration of the TRAIL gene driven by the hTERT promoter," <i>Cancer Gene Therapy</i> 12:109-15 (2005).	
		LI, X. et al., "Anti-tumor efficacy of a transcriptional replication-competent adenovirus, Ad-OC-E1a, for osteosarcoma pulmonary metastasis," <i>J. Gene Med.</i> 8:679-89 (2006).	
		LUI, V. et al., "Systemic Administration of Naked DNA Encoding Interleukin 12 for the Treatment of Human Papillomavirus DNA-Positive Tumor," <i>Human Gene Therapy</i> 13:177-85 (2002).	
		MAJUMDAR, A. et al., "The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters," <i>Gene Therapy</i> 8:568-78 (2001).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Substitute for form 1449/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number	11/471,916	
			Filing Date	June 20, 2006	
			First Named Inventor	Joseph D. Gold	
			Art Unit	1636	
			Examiner Name	Not Yet Assigned	
Sheet	2	of	2	Attorney Docket Number	099/041

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Trans
		PRADOS, M. et al., "Treatment of progressive or recurrent glioblastoma multiforme in adults with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration: a phase I/II multi-institutional trial," <i>J. Neuro-Oncology</i> 65:269-78 (2003).	
		WIRTH, T. et al., "A Telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer," <i>Cancer Res.</i> 63:3181-88 (2003).	
		WU, X. et al., "Systemic administration of naked DNA with targeting specificity to mammalian kidneys," <i>Gene Therapy</i> 12:477-86 (2005).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--